Citation Impact
Citing Papers
The ɛ-(γ-Glutamyl)Lysine Crosslink and the Catalytic Role of Transglutaminases
1977
Hypoxia-Inducible Factors in Physiology and Medicine
2012 StandoutNobel
Mechanisms of Thrombus Formation
2008 Standout
Prevention of Deep Vein Thrombosis after Elective Hip Surgery
1991
Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition
2005
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
2005
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Further subclassification of ATP receptors based on agonist studies
1991
Structural requirements for glycosyl‐phosphatidylinositol‐anchor attachment in the cellular receptor for urokinase plasminogen activator
1992
Strategies for the inhibition of serine proteases
2001
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms
2004
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
2005 Standout
Signalling Pathways in the Unfolded Protein Response: Development from Yeast to Mammals
2009
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Regulated portals of entry into the cell
2003 StandoutNature
Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness
1993
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
2005 Standout
Novel amidine-containing peptidyl phosphonates as irreversible inhibitors for blood coagulation and related serine proteases
1994
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
2003
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Heparin lowers plasma levels of activated factor VII
1999
Platelet Activation and Atherothrombosis
2007 Standout
The urokinase-type plasminogen activator system in cancer metastasis: A review
1997 Standout
Synthesis and kinetic studies of an amidine-containing phosphonofluoridate: a novel potent inhibitor of trypsin-like enzymes
1998
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
Tissue Plasminogen Activator Contributes to the Late Phase of LTP and to Synaptic Growth in the Hippocampal Mossy Fiber Pathway
1998 StandoutNobel
The microenvironment of the tumour–host interface
2001 StandoutNature
Cell-Associated Plasminogen Activation: Regulation and Physiological Functions
1988
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Heparin and Low-Molecular-Weight Heparin
1998
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
Identification of the haemoglobin scavenger receptor
2001 StandoutNature
Microglia‐Derived Elastase Produces a Low‐Molecular‐Weight Plasminogen that Enhances Neurite Outgrowth in Rat Neocortical Explant Cultures
1993
Caveolae: From Cell Biology to Animal Physiology
2002
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice
2004
Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma
1994 Standout
Atherosclerosis — An Inflammatory Disease
1999 Standout
Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α
1999 StandoutNobel
Genetics and pathogenesis of inflammatory bowel disease
2011 StandoutNature
Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk
2004
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Disseminated Intravascular Coagulation
1999 Standout
Heparin
1991
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Biochemical and biological aspects of the plasminogen activation system
1990
IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response
2002
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Hemorrhagic Complications of Anticoagulant Treatment
2001 Standout
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program
2003
Pharmacotherapeutic Aspects of Unfractionated and Low Molecular Weight Heparins
1990
Hemorrhagic Complications of Anticoagulant Treatment
2004
Outpatient treatment of deep vein thrombosis: translating clinical trials into practice
1999
Remarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry
2011
Conformation of one- and two-chain high molecular weight urokinase analyzed by small-angle neutron scattering and vacuum ultraviolet circular dichroism
1991 StandoutNobel
Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin
1991
Cellular Effects of Heparin on the Production and Release of Tissue Factor Pathway Inhibitor in Human Endothelial Cells in Culture
1999
Optimal Therapeutic Level of Heparin Therapy in Patients With Venous Thrombosis
1992
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
1989
Expression cloning of an ATP receptor from mouse neuroblastoma cells.
1993 StandoutNobel
Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
1990
Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
1992
Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol
1991
Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations
2000 StandoutNobel
The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards
1984
Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors
1989
Desensitization and antagonism of vasopressin-induced phosphoinositide metabolism and elevation of cytosolic free calcium concentration in human platelets
1986
Regulation of adrenergic receptor function by phosphorylation. I. Agonist-promoted desensitization and phosphorylation of alpha 1-adrenergic receptors coupled to inositol phospholipid metabolism in DDT1 MF-2 smooth muscle cells.
1987 StandoutNobel
Subcutaneous administration of heparin a randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis
1982
Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-Inducible Factors 1 and 2
2012 StandoutNobel
Regulation of basal cellular physiology by the homeostatic unfolded protein response
2010
Low molecular weight heparin
1992
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.
1994
The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation
2011 StandoutScience
Copper-Catalyzed Synthesis of Mixed Alkyl Aryl Phosphonates
2014 StandoutNobel
Inhibition of Trypsin and Thrombin by Amino(4-amidinophenyl)methanephosphonate Diphenyl Ester Derivatives: X-ray Structures and Molecular Models,
1996
The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
1996
Warfarin
1984
Evidence for Activation of Tissue Factor by an Allosteric Disulfide Bond
2006
Function of IRE1 alpha in the placenta is essential for placental development and embryonic viability
2009 StandoutNobel
The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.
1990
The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin
1981
Two Daily Subcutaneous Injections of Fragmin as Compared with Intravenous Standard Heparin in the Treatment of Deep Venous Thrombosis (DVT)
1990
Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
1990 StandoutNobel
In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
1990
Rational Tuning of Fluorobenzene Probes for Cysteine‐Selective Protein Modification
2018 StandoutNobel
Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product
1991 StandoutScience
Liver Regeneration
1997 StandoutScience
Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.
1994 StandoutNobel
Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.
1990
Posttranslational processing of the LDL receptor and its genetic disruption in familial hypercholesterolemia
1982 StandoutNobel
The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.
1990
Adjusted Subcutaneous Heparin or Continuous Intravenous Heparin in Patients with Acute Deep Vein Thrombosis
1987
Low-Molecular-Weight Heparins
1997 Standout
Disseminated intravascular coagulation due to malignancy.
1990
An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
1993 Standout
Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial.
1987
Enhanced sensitivity to DSS colitis caused by a hypomorphic Mbtps1 mutation disrupting the ATF6-driven unfolded protein response
2009 StandoutNobel
Management of Deep Vein Thrombosis and Pulmonary Embolism
1996
Kinetics of factor Xa inhibition by tissue factor pathway inhibitor.
1993
Pathophysiologic Implications of Membrane Phospholipid Asymmetry in Blood Cells
1997
Treatment of Venous Thromboembolism
1999
MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands
2010 StandoutNobel
The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin
1987
Smooth Muscle Cells Isolated From Discrete Compartments of the Mature Vascular Media Exhibit Unique Phenotypes and Distinct Growth Capabilities
1997
Clinical relevance of distal deep vein thrombosis. Review of literature data.
2006
Tumors: Wounds That Do Not Heal
1986 Standout
HIF-1 and human disease: one highly involved factor
2000 StandoutNobel
Synthesis of phosphonopeptides as thrombin inhibitors
1992
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
2002 Standout
Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers
1986
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.
1990
The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation.
1990 StandoutNobel
Low molecular weight heparin
1992
Lipid rafts are necessary for tonic inhibition of cellular tissue factor procoagulant activity
2004
Extracellular ATP: effects, sources and fate
1986 Standout
Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung
1998 StandoutNobel
Works of Michael Scully being referenced
Inhibition of human α-thrombin by a phosphonate tripeptide proceeds via a metastable pentacoordinated phosphorus intermediate 1 1Edited by R. Huber
2001
Mercury compounds induce a rapid increase in procoagulant activity of monocyte‐like U937 cells
1994
Activation of pro-urokinase by plasmin: Non-michaelian kinetics indicates a mechanism of negative cooperativity
1989
Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo
2001
Chrono-Pharmacological Study of Once Daily Curative Dose of a Low Molecular Weight Heparin (200IU antiXa/kg of Dalteparin) in Ten Healthy Volunteers
1995
The acceleration of the inhibition of platelet prothrombinase complex by heparin
1986
An objective study of alternative methods of heparin administration
1980
The relative molecular mass dependence of the anti-factor Xa properties of heparin
1986
Inhibition of human factor Xa by various plasma protease inhibitors
1982
Benzyloxycarbonyl-d -Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position
1993
Thrombin Induces the Redistribution and Acute Release of Tissue Factor Pathway Inhibitor From Specific Granules Within Human Endothelial Cells in Culture
1995
Tissue Factor Pathway Inhibitor in Endothelial Cells Colocalizes With Glycolipid Microdomains/Caveolae
1997
Decrease in Factor VII Coagulant Activity during Percutaneous Transluminal Coronary Angioplasty by Heparin-Mediated Lipolytic Action
1997
In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor.
1993
Role of subunit crosslinking in fibrin solubility
1976
A comparative study of low doses of heparin and a heparin analogue in the prevention of postoperative deep vein thrombosis
1978
Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study.
1987
Evidence for Cultured Human Vascular Smooth Muscle Cell Heterogeneity: Isolation of Clonal Cells and Study of their Growth Characteristics
1996
Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulphate (SP54)
1984
An experimental model for the study of venous thrombosis in vivo
1974
The behaviour of isotope labelled blood proteins in thrombosis
1974
Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces.
1994
Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo
2001
Plasminogen Activation Initiated by Single-chain Urokinase-type Plasminogen Activator
1989
Substrate-related phosphonopeptides, a new class of thrombin inhibitors
1991
Mechanisms of Stimulus—Response Coupling in Platelets
1986